|
审核状态: Project audit state: |
通过审核 Successful |
|
注册号: Registration number: |
ChiCTR2600118265 |
|
最近更新日期: Date of Last Refreshed on: |
2026-02-03 17:54:26 |
|
注册时间: Date of Registration: |
2026-02-03 00:00:00 |
|
注册号状态: |
预注册 |
|
Registration Status: |
Prospective registration |
|
注册题目: |
ICU幸存者核心症状智能化随访及干预研究 |
|
Public title: |
Intelligent Follow-up and Intervention on Core Symptoms of ICU Survivors |
|
注册题目简写: |
IFICS-ICUS |
|
English Acronym: |
IFICS-ICUS |
|
研究课题的正式科学名称: |
基于核心症状的 ICU 幸存者专科智随访路径构建及应用 |
|
Scientific title: |
A specialized intelligent follow-up protocol for ICU survivors: Focusing on Core Symptom Management |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
黄艳林 |
研究负责人: |
黄艳林 |
|
Applicant: |
Huang Yanlin |
Study leader: |
Huang Yanlin |
|
申请注册联系人电话: Applicant telephone: |
+86 136 6215 8930 |
研究负责人电话: Study leader's telephone: |
+86 136 6215 8930 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
huangyanlin@tju.edu.cn |
研究负责人电子邮件: Study leader's E-mail: |
huangyanlin@tju.edu.cn |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
天津市河东区津塘路83号 |
研究负责人通讯地址: |
天津市河东区津塘路83号 |
|
Applicant address: |
83 Jintang Road, Hedong District, Tianjin |
Study leader's address: |
83 Jintang Road, Hedong District, Tianjin |
|
申请注册联系人邮政编码: Applicant postcode: |
研究负责人邮政编码: Study leader's postcode: |
||
|
申请人所在单位: |
天津大学中心医院/天津市第三中心医院 |
||
|
Applicant's institution: |
Central Hospital, Tianjin University /Tianjin Third Central Hospital |
||
|
研究负责人所在单位: |
天津大学中心医院/天津市第三中心医院 |
||
|
Affiliation of the Leader: |
Central Hospital, Tianjin University /Tianjin Third Central Hospital |
||
|
是否获伦理委员会批准: |
是/Yes |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
IRB2025-088-01 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
天津市第三中心医学伦理委员会第六届第八十次会议 |
||
|
Name of the ethic committee: |
The Eightieth Meeting of the Sixth Session of the Tianjin Third Central Hospital Medical Ethics Committee |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2026-01-05 00:00:00 |
||
|
伦理委员会联系人: |
董俊宏 |
||
|
Contact Name of the ethic committee: |
Dong Junhong |
||
|
伦理委员会联系地址: |
天津市河东区津塘路83号 |
||
|
Contact Address of the ethic committee: |
83 Jintang Road, Hedong District, Tianjin |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
+86 22 8411 2369 |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
|
|
研究实施负责(组长)单位: |
天津大学中心医院/天津市第三中心医院 |
||||||||||||||||||||||
|
Primary sponsor: |
Central Hospital, Tianjin University /Tianjin Third Central Hospital |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
天津市河东区津塘路83号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
83 Jintang Road, Hedong District, Tianjin |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
天津市卫生健康科技项目(TJWJ2025QN059) |
||||||||||||||||||||||
|
Source(s) of funding: |
Tianjin Health Science and Technology Project(TJWJ2025QN059) |
||||||||||||||||||||||
|
Target disease: |
Post-ICU syndrome |
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
干预性研究 |
||||||||||||||||||||||
|
Study type: |
Interventional study |
||||||||||||||||||||||
|
研究所处阶段: |
其它 | ||||||||||||||||||||||
|
Study phase: |
N/A |
||||||||||||||||||||||
|
研究设计: |
随机平行对照 |
||||||||||||||||||||||
|
Study design: |
Parallel |
||||||||||||||||||||||
|
研究目的: |
基于症状管理理论,通过纵向调研明确ICU幸存者核心症状,确定随访干预靶点;基于智随访平台构建ICU幸存者专科智随访路径,明确干预时机、干预内容等,以期提高ICU幸存者随访效率,减轻症状困扰,提高健康相关生活质量,改善预后。 |
||||||||||||||||||||||
|
Objectives of Study: |
Based on symptom management theory, longitudinal investigation will be employed to identify the core symptoms in ICU survivors and determine targeted follow-up interventions. Utilizing an intelligent follow-up platform, a specialized digital follow-up pathway for ICU survivors will be developed, specifying intervention timing and content. This approach aims to enhance follow-up efficiency, alleviate symptom burden, improve health-related quality of life, and optimize long-term outcomes for ICU survivors. |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
1.年龄>=18周岁; 2.ICU住院时间>=24小时; 3.ICU转出后存活时间>=7天; 4.至少存在一种核心症状; 5.知情同意,自愿参与本研究 |
||||||||||||||||||||||
|
Inclusion criteria |
1. Age >= 18 years; 2. ICU stay >= 24 hours; 3. survival time after ICU transfer >= 7 days; 4. presence of at least one core symptom; 5. informed consent and voluntary participation in the study |
||||||||||||||||||||||
|
排除标准: |
1.理解、沟通能力存在严重障碍,不能通过任意方式表达自己想法者; 2.转出后48小时内重返ICU; 3.转出后72h出院者; 4.预计生存期小于6个月 |
||||||||||||||||||||||
|
Exclusion criteria: |
1. Those who have serious impairment in understanding and communication and cannot express their thoughts through arbitrary means; 2. those who return to ICU within 48h after transfer out; 3. those who are discharged 72h after transfer; 4. Expected survival period is less than 6 months |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2026-01-05 00:00:00至 To 2028-06-30 00:00:00 |
征募观察对象时间: Recruiting time: |
从From 2026-02-03 00:00:00 至 To 2028-06-30 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
正在进行 Recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
研究人员通过计算机生成随机序列 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
The investigators generated the random sequence by computer |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
不公开/Private |
|
盲法: |
对数据评价及数据分析人员实施盲法 |
|
Blinding: |
Outcome assessors and data analysts will be blinded |
|
是否共享原始数据: IPD sharing |
No |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
无 |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
None |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
病例记录表 项目负责人统一管理 |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
Case Record Form, uniformly managed by the principal investigator |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
暂未确定/Not yet |